IL316867A - Macrocyclic inhibitors of kras for the treatment of cancer - Google Patents
Macrocyclic inhibitors of kras for the treatment of cancerInfo
- Publication number
- IL316867A IL316867A IL316867A IL31686724A IL316867A IL 316867 A IL316867 A IL 316867A IL 316867 A IL316867 A IL 316867A IL 31686724 A IL31686724 A IL 31686724A IL 316867 A IL316867 A IL 316867A
- Authority
- IL
- Israel
- Prior art keywords
- kras
- cancer
- treatment
- macrocyclic inhibitors
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022103694 | 2022-07-04 | ||
| CN2022124638 | 2022-10-11 | ||
| CN2023070765 | 2023-01-05 | ||
| CN2023087633 | 2023-04-11 | ||
| PCT/EP2023/068154 WO2024008610A1 (en) | 2022-07-04 | 2023-07-03 | Macrocyclic inhibitors of kras for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316867A true IL316867A (en) | 2025-01-01 |
Family
ID=87155635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316867A IL316867A (en) | 2022-07-04 | 2023-07-03 | Macrocyclic inhibitors of kras for the treatment of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250257075A1 (en) |
| EP (1) | EP4551578A1 (en) |
| JP (1) | JP2025522629A (en) |
| KR (1) | KR20250029239A (en) |
| CN (1) | CN119546612A (en) |
| AR (1) | AR129819A1 (en) |
| AU (1) | AU2023303814A1 (en) |
| CA (1) | CA3261042A1 (en) |
| CL (1) | CL2024004085A1 (en) |
| CO (1) | CO2024017733A2 (en) |
| CR (1) | CR20240563A (en) |
| IL (1) | IL316867A (en) |
| MA (1) | MA71370A (en) |
| MX (1) | MX2024015363A (en) |
| PE (1) | PE20250843A1 (en) |
| TW (1) | TW202408507A (en) |
| WO (1) | WO2024008610A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240088A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| PE20252395A1 (en) | 2023-02-14 | 2025-10-10 | Hoffmann La Roche | TRICYCLIC COMPOUNDS FOR CANCER TREATMENT |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (en) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | Macrocyclic RAS inhibitors |
| KR20260019479A (en) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Combination therapy for RAS-related diseases or disorders |
| CN121889155A (en) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | RMC-6291 for the treatment of RAS protein-related diseases or disorders |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026021499A1 (en) * | 2024-07-24 | 2026-01-29 | 苏州泽璟生物制药股份有限公司 | Haloalkylene substituted cycloalkyl or heterocyclic inhibitor, and preparation method therefor and use thereof |
| TW202615038A (en) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (en) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Ras inhibitors. |
| EP4208261A1 (en) * | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
-
2023
- 2023-07-03 AR ARP230101730A patent/AR129819A1/en unknown
- 2023-07-03 WO PCT/EP2023/068154 patent/WO2024008610A1/en not_active Ceased
- 2023-07-03 KR KR1020257003428A patent/KR20250029239A/en active Pending
- 2023-07-03 JP JP2025500043A patent/JP2025522629A/en active Pending
- 2023-07-03 CA CA3261042A patent/CA3261042A1/en active Pending
- 2023-07-03 PE PE2024003109A patent/PE20250843A1/en unknown
- 2023-07-03 CN CN202380051654.4A patent/CN119546612A/en active Pending
- 2023-07-03 CR CR20240563A patent/CR20240563A/en unknown
- 2023-07-03 IL IL316867A patent/IL316867A/en unknown
- 2023-07-03 AU AU2023303814A patent/AU2023303814A1/en active Pending
- 2023-07-03 MA MA71370A patent/MA71370A/en unknown
- 2023-07-03 TW TW112124777A patent/TW202408507A/en unknown
- 2023-07-03 EP EP23738471.4A patent/EP4551578A1/en active Pending
-
2024
- 2024-12-11 MX MX2024015363A patent/MX2024015363A/en unknown
- 2024-12-19 US US18/987,316 patent/US20250257075A1/en active Pending
- 2024-12-23 CO CONC2024/0017733A patent/CO2024017733A2/en unknown
- 2024-12-30 CL CL2024004085A patent/CL2024004085A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024008610A1 (en) | 2024-01-11 |
| KR20250029239A (en) | 2025-03-04 |
| CA3261042A1 (en) | 2024-01-11 |
| MA71370A (en) | 2025-04-30 |
| AU2023303814A1 (en) | 2024-11-21 |
| EP4551578A1 (en) | 2025-05-14 |
| PE20250843A1 (en) | 2025-03-21 |
| CN119546612A (en) | 2025-02-28 |
| AR129819A1 (en) | 2024-10-02 |
| TW202408507A (en) | 2024-03-01 |
| CL2024004085A1 (en) | 2025-03-21 |
| JP2025522629A (en) | 2025-07-15 |
| US20250257075A1 (en) | 2025-08-14 |
| CR20240563A (en) | 2025-02-14 |
| CO2024017733A2 (en) | 2025-01-13 |
| MX2024015363A (en) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3261042A1 (en) | Macrocyclic inhibitors of kras for the treatment of cancer | |
| IL316706A (en) | Macrocycle compounds for the treatment of cancer | |
| AU2024380740A1 (en) | Macrocyclic compounds as kras mutant inhibitors for the treatment of cancer | |
| IL287838A (en) | Dosing of kras inhibitor for treatment of cancers | |
| IL308195A (en) | Ras inhibitors for the treatment of cancer | |
| ES3065771T3 (en) | Substituted oxoisoindoline compounds for the treatment of cancer | |
| IL325744A (en) | Combination therapies for the treatment of cancer | |
| IL316829A (en) | Menin-mll inhibitors for the treatment of cancer | |
| IL288707A (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| IL304595A (en) | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | |
| IL312650A (en) | Cdk4 inhibitor for the treatment of cancer | |
| IL321393A (en) | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | |
| IL305780A (en) | Methods for the treatment of cancer | |
| IL314687A (en) | Treatment of cancer | |
| IL315444A (en) | Expression system for the treatment of cancer | |
| CA3294919A1 (en) | Omomyc and kras inhibitors combination therapy for the treatment of cancer | |
| GB202508597D0 (en) | Compounds for the treatment of cancer | |
| IL318624A (en) | Combination therapies for treatment of cancer | |
| EP4452946A4 (en) | Compounds for treatment of cancer | |
| HK40061296A (en) | Dosing of kras inhibitor for treatment of cancers | |
| HK40084369A (en) | Inhibitors of mlh1 and/or pms2 for cancer treatment | |
| GB202311976D0 (en) | Treatment of cancer | |
| HK40093971A (en) | Smarca4 inhibition for the treatment of cancer | |
| CA3303484A1 (en) | Bet inhibitors for the treatment of cancer | |
| GB202218181D0 (en) | Treatment of cancer |